Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 12/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25236450 | 1.00 | C5AR1 (0.41) | C5AR1P2RX3OPRD1OPRK1OPRL1 | |
| SCHEMBL25213573 | 1.00 | C5AR1 (0.41) | C5AR1P2RX3OPRD1OPRK1OPRL1 | |
| SCHEMBL25576131 | 0.87 | C5AR1 (0.45) | C5AR1P2RX3OPRD1OPRL1 | |
| SCHEMBL30469200 | 0.87 | C5AR1 (0.45) | C5AR1P2RX3OPRD1OPRL1 | |
| SCHEMBL30469180 | 0.87 | C5AR1 (0.45) | C5AR1P2RX3OPRD1OPRL1 | |
| SCHEMBL30469182 | 0.87 | C5AR1 (0.45) | C5AR1P2RX3OPRD1OPRL1 | |
| SCHEMBL25214923 | 0.87 | C5AR1 (0.45) | C5AR1P2RX3OPRD1OPRL1 | |
| SCHEMBL25576129 | 0.87 | C5AR1 (0.45) | C5AR1P2RX3OPRD1OPRL1 | |
| SCHEMBL25250725 | 0.84 | TRPV3 (0.38) | C5AR1OPRD1OPRK1OPRL1 | |
| SCHEMBL31067853 | 0.84 | TRPV3 (0.38) | C5AR1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |